Navigation Links
HUYA Bioscience International Forms Alliance With Zhejiang Chinese Medical University Life Science College
Date:9/8/2011

SAN DIEGO, Calif., Sept. 8, 2011 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's pharmaceutical innovations, today announced a strategic partnership with the Zhejiang Chinese Medical University Life Science College. The collaboration agreement will accelerate the global drug development of China's novel Traditional Chinese Medicines (TCM).

The partnership is expected to bring productive synergy between the two parties. Zhejiang Chinese Medical University Life Science College, a prominent traditional Chinese medicine university in southern China, is recognized for its strength in leading-edge research in TCM.  HUYA has a strong commitment toward developing novel therapeutics from TCM in areas of unmet medical needs.  HBI-3000, HUYA's novel anti-arrhythmic compound currently in development in both China and the U.S., was originally derived from a TCM.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing innovative compounds from the country, utilizing its expertise to advance these compounds for global markets.

"The alliance with Zhejiang Chinese Medical University Life Science College will further strengthen HUYA's collaborative efforts with the faculty and researchers of the university," said Clement Gingras, HUYA's CTO and COO, China. "Together, HUYA and Zhejiang Chinese Medical University Life Science College will help advance the progression of TCM to the global markets, benefiting patients worldwide."

Dr. Zhishan Ding, Associate Dean of Zhejiang Chinese Medical University Life Science Colleg
'/>"/>

SOURCE HUYA Bioscience International
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad
2. Avantra Biosciences Changes Company Name to Courtagen Life Sciences, Inc.
3. BD Biosciences Announces Winners of Research Grant Program
4. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
5. Numira Biosciences Names New Board Member
6. Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
7. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
8. BioMed Realty Trust and BIND Biosciences Sign New Lease at Vassar Street Property
9. Neurocrine Biosciences Reports Second Quarter 2011 Results
10. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
11. Roka Bioscience Participates in the International Association for Food Protection Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Esperance Pharmaceuticals Inc. today reported positive results ... in ovarian cancer patients resistant to paclitaxel. EP-100 is ... cancer cells that overexpress luteinizing hormone-releasing hormone (LHRH) receptors ... wide range of cancers. Results of ... were presented at the 2015 ASCO Annual Meeting ...
(Date:6/1/2015)... June 1, 2015  Berg, a biopharmaceutical company committed ... presented clinical research from its trials using its cancer ... preclinical data on triple negative breast cancer, at the ... of Clinical Oncology (ASCO), May 29 – June 2 ... BPM 31510 is one of the first cancer drugs ...
(Date:6/1/2015)... , June 1, 2015  Albany ... announced today that it has signed a ... to co-market their structure-based drug discovery services ... part of the three-year agreement, AMRI gains ... expertise and capabilities. HarkerBIO,s customers will be ...
(Date:6/1/2015)... 29, 2015 Research and Markets( ... the "2015 Strategies in the US ... their offering. This new 373-page ... comprehensive analysis of the POC clinical chemistry ... requirements, technological trends, competitive landscape, and emerging ...
Breaking Biology Technology:Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 2AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 3
... 2008, Abbott,s,( NYSE: ABT ) employee giving in the ... number of participating employees and total dollar contributions,despite difficult ... Abbott,employees (74 percent) participated in the company,s employee giving ... contributed more than $12.6,million to non-profit groups in 2008, ...
... Offering , ... Rochester, New York ... innovator in advanced cardiac safety biomakers and automated QT analysis, ... as its quarter over quarter revenues have grown in excess ...
... Belgium and LUND, Sweden, February 23 , ... of Partial Factor VIII Inhibition in,Patients Undergoing Knee Replacement ... Brussels: THR) and co-development partner,BioInvent International (OMXS: BINV) announce ... Phase II trial with their long-acting anticoagulant,TB-402 for the ...
Cached Biology Technology:Abbott Employee Giving Sets New Records for Employee Participation and Total Donations 2Abbott Employee Giving Sets New Records for Employee Participation and Total Donations 3iCardiac Reports Significant Revenue Growth and Profitability 2iCardiac Reports Significant Revenue Growth and Profitability 3ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 2ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 3ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 4ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 5
(Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... a new model to predict the impact of climate change ... Australia information that could help limit its spread. ... of the British Ecological Society,s journal Functional Ecology , ... and expand the mosquito,s range. But human behaviour in ...
... Institute at Arizona State University associate research scientist Melha Mellata, ... USDA funded project to develop a vaccine against a leading ... APEC is part of a large, diverse group ... They cause a number of complex brain, lung and urinary ...
... January 2009. The Alfred Wegener Institute for Polar ... conduct the ongoing Polarstern expedition LOHAFEX". Independent scientific ... of Education and Research and the Federal Ministry ... concluded that the iron fertilisation experiment LOHAFEX is ...
Cached Biology News:Hoarding rainwater could 'dramatically' expand range of dengue-fever mosquito 2New insights into a leading poultry disease and its risks to human health 2New insights into a leading poultry disease and its risks to human health 3New insights into a leading poultry disease and its risks to human health 4Polarstern expedition 'LOHAFEX' can be conducted 2Polarstern expedition 'LOHAFEX' can be conducted 3
... Ion Channel Cell Lines ,High Quality, Functionally-Validated, ... are well known for having a critical ... consequently have a key function in pain, ... ion channels have been investigated in therapeutic ...
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
... Protein Staining Solution stains proteins ... electrophoresis (detection limit >= 8 ng ... including washing and destaining processes can ... staining of gel (20 min), proteins ...
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Biology Products: